ClinicalTrials.gg

Program

Menin Inhibitor AZD3632

Its studies are mostly in Precursor Cell Lymphoblastic Leukemia-Lymphoma, led by AstraZeneca.

Furthest: phase 2, since Aug 14, 20251 company-led study, 1 open or runningNext primary completion: Feb 15, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 2since Aug 14, 2025Aug 14, 2025Feb 15, 2029phase 2 · NCT07155226
  • Named in AstraZeneca’s own pipeline as AZD3632, phase 1, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 14, 2025First study: phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaFirst studyNCT07155226 · 85 planned · United States, Australia, Canada and more

Ahead

  1. Feb 15, 2029Primary completion: phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT07155226

TargetBeta

“An orally bioavailable small molecule inhibitor of menin, with potential antineoplastic activity. Upon oral administration, menin inhibitor AZD3632 targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and menin-mixed lineage leukemia (M…”NCIt, read by Claude

Other programs on MEN1

ProgramCompanyFurthest phaseStudies
revumenibruleSyndax Pharmaceuticalsphase 36
bleximenibJohnson & Johnsonphase 34

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07155226Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, Australia, Canada and more2RecruitingFeb 15, 202985

How it is read

Names in the registry

  • “AZD3632”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.